Does teriparatide reverse osteonecrosis of the jaw in patients with cancer? A randomised, controlled trial [ 2012 - 2015 ]

Research Grant

Researchers: Prof Peter Ebeling (Principal investigator) ,  A/Pr Gelsomina Borromeo ,  Prof John Seymour

Brief description Osteonecrosis of the jaw (ONJ) is debilitating and associated with drugs that increase bone strength and reduce the bone remodeling rate (bisphosphonates or denosumab). Up to 15% of patients with bone marrow cancer and 1 out of 952 patients with osteoporosis treated with bisphosphonates may get ONJ. This 8-week trial of subcutaneous teriparatide (a hormone that forms new bone) or placebo injections aims to promote resolution of ONJ, measured clinically and by x-ray, and improve quality of life.

Funding Amount $AUD 357,412.09

Funding Scheme Project Grants

Notes Standard Project Grant